Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 72 clinical trials
Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist

Novel, non-vitamin K antagonist oral anticoagulants (NOAC) target selected players in the coagulation cascade as the direct thrombin inhibitor dabigatran and the factor Xa-inhibitors apixaban

hematoma
noac
anticoagulants
rivaroxaban
apixaban
  • 19 views
  • 25 Jan, 2021
  • 1 location
Impact of Early Debriefing and Enhanced Educative Components on Direct Oral Anticoagulant Adherence After Venous Thromboembolism.

and educative components added to a standardized visit one month after an acute VTE has the potential to improve patient's adherence to APIXABAN therapy at 6 months of follow-up.

apixaban
anticoagulation therapy
anticoagulants
  • 1 views
  • 26 Jan, 2021
  • 15 locations
Avoiding Anticoagulation After IntraCerebral Haemorrhage

Randomised controlled trials (RCTs) demonstrate a substantial benefit from oral anticoagulant drugs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (AF). However, these RCTs excluded patients with prior intracerebral haemorrhage (ICH). Therefore, guidelines are unable to recommend whether oral anticoagulant drugs, in particular non-vitamin K antagonist …

stroke
anticoagulation therapy
fibrillation
vitamin k antagonist
vitamin k
  • 0 views
  • 25 Jan, 2021
  • 2 locations
Ultrasound-guided Axillary Versus Conventional Cephalic Venous Access for Implantation of Cardiac Devices

The implantation of cardiac electronic devices is a common procedure in the Electrophysiology Laboratory. The most commonly used venous access sites are the cephalic, the axillary and the subclavian vein. Studies comparing these options have been conducted in the past. Axillary venous access can be achieved either through axillary vein …

  • 0 views
  • 20 Jul, 2021
  • 1 location
Efficacy of a Didactic Intervention in Anticoagulated Patients (TAOPE Study)

Background: Oral anticoagulant drugs represent an essential tool in thrombo-embolic events prevention. Most used are vitamin K antagonists (VKA), which plasma level is monitored measuring prothrombin time using the International Normalized Ratio. If it takes values out of recommended range, the patient will have a higher risk of suffering from …

  • 1 views
  • 22 Jan, 2021
  • 2 locations
EHR-Embedded Decision Support to Prevent Stroke in Patients With AF

Background and Significance - Atrial fibrillation (AF) is the most common significant cardiac rhythm disorder and is a powerful common risk factor for stroke. Randomized trials have demonstrated that anticoagulation can reduce the risk of stroke in patients with AF. Yet, there continues to be widespread underutilization of this therapy. …

  • 0 views
  • 08 May, 2021
  • 1 location
Safety and Efficacy of Apixaban in Very Old Geriatric Subjects (> 80 Years) With Atrial FIbrillation in a Prospective reAl World Study;

Atrial fibrillation (AF) newly treated with Apixaban. Moreover, in this geriatric population the adequacy of Apixaban dosage and events (bleeding and stroke) will be assessed.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Sub-Clinical Atrial Fibrillation Biomarker Study

This is a sub-study of the ARTESiA study registered as NCT01938248. This study is designed to validate biomarkers in subclinical atrial fibrillation and to determine if the prospective biomarker will be informative of the potential efficacy of treatment.

  • 8 views
  • 07 May, 2021
  • 1 location
A Multi-center Study of Apixaban(APPROACH)

The aim of the study is to enroll approximately 200 cases from 10 research centers nationwide, completed left atrial appendage occlusion (LAAO) successfully, and give apixaban (5 mg bid

  • 0 views
  • 25 Jan, 2021
  • 1 location
Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants

(include rivaroxaban, apixaban, dabigatran and so on) have advantages of convenient use and no need of monitoring, compared with the traditional vitamin K antagonist. With lack of predicted biomarkers

  • 7 views
  • 28 Jan, 2021
  • 21 locations